Cargando…

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30). DESIGN: Sixte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niskanen, Leo, Leiter, Lawrence A, Franek, Edward, Weng, Jianping, Damci, Taner, Muñoz-Torres, Manuel, Donnet, Jean-Paul, Endahl, Lars, Skjøth, Trine Vang, Vaag, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioScientifica 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400040/ https://www.ncbi.nlm.nih.gov/pubmed/22660026 http://dx.doi.org/10.1530/EJE-12-0293

Ejemplares similares

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
por: Franek, E., et al.
Publicado: (2015)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
por: Evans, Marc, et al.
Publicado: (2016)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2016)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
por: Mehta, Roopa, et al.
Publicado: (2020)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
por: Lane, Wendy S., et al.
Publicado: (2020)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
por: Glastras, Sarah J., et al.
Publicado: (2020)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
por: Demir, Tevfik, et al.
Publicado: (2021)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
por: Kumar, Ajay, et al.
Publicado: (2016)

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
por: Raja-Khan, Nazia, et al.
Publicado: (2007)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Agadir cohort of the A(1)chieve study
por: Boussouf, Hicham, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Marrakech cohort of the A(1)chieve study
por: Nawal, El Ansari
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Casablanca cohort of the A(1)chieve study
por: Farouqi, Ahmed, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A(1)chieve study
por: Ajdi, Farida
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A(1)chieve study
por: El Harby, Moody, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A(1)chieve study
por: Atef, Zayed, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bahraini cohort of the A(1)chieve study
por: Hussein, Wiam Ibrahim, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A(1)chieve study
por: Daban, Alaa, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Qatar cohort of the A(1)chieve study
por: Daghash, Mohamed Hasan, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Dubai cohort of the A(1)chieve study
por: Gulzar, Zain, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A(1)chieve study
por: Al Abousi, Mustafa
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A(1)chieve study
por: Phadke, Uday, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Mumbai cohort of the A(1)chieve study
por: Talwalkar, P. G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vap4v7iuu1ft5t2kd70jb3oqbb